JAN 16, 2019 09:00 AM PST

Predicting Response to Intravesical Immunotherapy with BCG

SPONSORED BY: Abbott Molecular
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Professor of Urology and Director of Urologic Oncology Fellowship, M.D. Anderson Cancer Center
    Biography
      Dr Ashish M. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at M.D. Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr Kamat's expertise is in multidisciplinary management of urologic cancers with an emphasis bladder and prostate cancer, organ sparing therapies, minimally invasive techniques, and orthotopic bladder substitution (neobladder). While he is a busy surgeon, he maintains an active research portfolio to improve the care of patients. Dr Kamat's efforts are directed towards identifying predictors of response to therapy - especially immunotherapy - as a first step towards personalized cancer therapeutics. A major focus of his laboratory research is to develop novel treatments for bladder cancer and identify resistance mechanisms and ways to overcome them. He serves as project PI on the MD Anderson Cancer Center GU (Bladder) SPORE. He has authored over 200 publications, editorials & book chapters in prestigious journals; he is listed in'Who's Who in Medicine' and 'Best Doctors in America' and has won the Compassionate Doctor Award from patient groups. He is an exceptional educator nominated twice for the Robert M. Chamberlain Distinguished Mentor Award and has been invited as a visiting professor to several universities across the world. Dr Kamat is also Co President,International Bladder Cancer Network, Chair, Bladder Cancer Think Tank (2015), Chair, Bladder Cancer Task Force for SITC, actively participates in various global urologic efforts, and serves on the board of regional and national societies for Urology.

    Abstract:

    DATE: January 16th, 2019

    TIME: 9:00AM PST, 12:00PM EST

    Dr. Kamat will present his clinical experience using molecular markers, in addition to the standard of care, to examine patient outcomes in the BCG response monitoring scenario.

    Learning Objectives:

    • Review of Bladder Cancer case studies to understand the use of BCG in bladder cancer subtypes
    • Understand BCG tolerance, patient response, and use of UroVysion

    Show Resources
    You May Also Like
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    JUN 29, 2018 09:00 AM PDT
    C.E. CREDITS
    JUN 29, 2018 09:00 AM PDT
    DATE: June 29, 2018TIME: 09:00AM PDT, 12:00PM EDT There is significant epidemiological evidence to suggest that the consumption of a high-broccoli diet is associated with a r...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    Loading Comments...